| Molecular Weight: | 514.52 |
| Formula: | C25H21F3N4O3S |
| Purity: | ≥98% |
| CAS#: | 1314890-29-3 |
| Solubility: | DMSO up to 50 mM |
| Chemical Name: | N-((4-(4-phenylthiazol-2-yl)tetrahydro-2H-pyran-4-yl)methyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide |
| Storage: | Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year. |
Biological Activity:
TMP269 is a highly potent, selective and cell-permeable class IIa HDAC inhibitor with IC50 of 126 nM, 80 nM, 36 nM and 19 nM for HDAC4, HDAC5, HDAC7 and HDAC9 respectively. It has very weak or no activity targeting the other HDACs (2-40 µM). TMP269 has an unprecedented metal-binding group, trifluoromethyloxadiazole (TFMO), which circumvents the selectivity and pharmacologic liabilities of hydroxamates. Crystallography revealed a direct metal binding of the TFMO, and the chemo-proteomics approach demonstrated the superior selectivity of TMP269 relative to the other hydroxamate-substituted analogs via a chelating zinc-binding group. TMP269 alters gene expression unlike class I and IIb HDAC inhibitors and affects colony-stimulating factor responses. The discovery of TMP269 provides an alternative design for targeting metalloenzymes than the conventional chelating metal-binding group, and suggests a therapeutic potential for class IIa HDAC inhibitors that are distinct in mechanism and application compared to current HDAC inhibitors.
How to Use:
- In vitro: TMP269 was suggested to be used at 3 µM final concentration in vitro and in cellular assays.
- In vivo: n/a
Reference:
- 1. Lobera M, et al. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. (2013) Nat Chem Biol. 9(5):319-25.
Products are for research use only. Not for human use.
